JPY 632.0
(-1.25%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 366.05 Million JPY | 226.88% |
2022 | -322.47 Million JPY | -58.81% |
2021 | -222.31 Million JPY | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | -192.7 Million JPY | 15.73% |
2024 Q1 | -228.68 Million JPY | -59.63% |
2023 Q3 | -135.27 Million JPY | 0.0% |
2023 Q4 | -143.25 Million JPY | -5.9% |
2023 FY | - JPY | 226.88% |
2022 FY | - JPY | -58.81% |
2021 FY | - JPY | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
KOHJIN BIO CO LTD | 958.1 Million JPY | 61.793% |
PRISM BioLab Co.,LTD | -488.13 Million JPY | 174.992% |
GNI Group Ltd. | 14.48 Billion JPY | 97.474% |
Linical Co., Ltd. | 1.24 Billion JPY | 70.65% |
Trans Genic Inc. | 240.95 Million JPY | -51.922% |
MEDINET Co., Ltd. | -1.35 Billion JPY | 126.998% |
Soiken Holdings Inc. | -583.2 Million JPY | 162.767% |
Cytori Cell Research Institute, Inc. | -603.09 Million JPY | 160.697% |
AnGes, Inc. | -8.86 Billion JPY | 104.132% |
OncoTherapy Science, Inc. | -1.28 Billion JPY | 128.476% |
Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 104.947% |
Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | -185.744% |
NanoCarrier Co., Ltd. | -863 Million JPY | 142.417% |
Carna Biosciences, Inc. | -1.09 Billion JPY | 133.528% |
CanBas Co., Ltd. | 53.65 Million JPY | -582.295% |
D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | 147.197% |
RaQualia Pharma Inc. | -111.8 Million JPY | 427.419% |
Chiome Bioscience Inc. | -1.21 Billion JPY | 130.209% |
Kidswell Bio Corporation | -1.38 Billion JPY | 126.51% |
PeptiDream Inc. | 7.37 Billion JPY | 95.037% |
Oncolys BioPharma Inc. | -1.92 Billion JPY | 118.97% |
Ribomic Inc. | -1.01 Billion JPY | 136.153% |
SanBio Company Limited | -4.52 Billion JPY | 108.09% |
Healios K.K. | -3 Billion JPY | 112.174% |
BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 131.4% |
Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 126.277% |
Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 126.11% |
StemRIM | -2.03 Billion JPY | 118.015% |
CellSource Co., Ltd. | 1.3 Billion JPY | 71.98% |
FunPep Company Limited | -952 Million JPY | 138.451% |
Kringle Pharma, Inc. | -888.76 Million JPY | 141.187% |
Stella Pharma Corporation | -723.85 Million JPY | 150.571% |
TMS Co., Ltd. | -937 Million JPY | 139.067% |
Noile-Immune Biotech Inc. | -775.39 Million JPY | 147.209% |
Cuorips Inc. | -518 Million JPY | 170.668% |
Takara Bio Inc. | 8.02 Billion JPY | 95.438% |
ReproCELL Incorporated | 8.24 Million JPY | -4339.757% |
PhoenixBio Co., Ltd. | 87.93 Million JPY | -316.268% |
StemCell Institute Inc. | 534.35 Million JPY | 31.495% |
Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | -49.525% |
CellSeed Inc. | -836.51 Million JPY | 143.76% |